SLS: SELLAS Life Sciences Group Inc. Stocks News on July 2, 2025

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

SLS

GlobeNewswire

8 days ago

SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes

We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

SLS

Simply Wall St.

11 days ago

We Think SELLAS Life Sciences Group (NASDAQ:SLS) Needs To Drive Business Growth Carefully

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

SLS

GlobeNewswire

a month ago

SELLAS Life Sciences Expands Scientific Advisory Board with Addition of Two World-Renowned Hematology and Oncology Experts

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

SLS

GlobeNewswire

a month ago

SELLAS Presents Preclinical Efficacy of SLS009 in ASXL1 Mutated Colorectal Cancer at 2025 ASCO Annual Meeting

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

SLS

GOBankingRates

a month ago

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

3 International Vacations That Are Cheaper Than an iPhone

SLS

GOBankingRates

a month ago

3 International Vacations That Are Cheaper Than an iPhone

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

SLS

GOBankingRates

a month ago

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

This week in Trumponomics: Too bad TACO isn’t true

SLS

Yahoo Finance

a month ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right

SLS

The Guardian

a month ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

SLS

Yahoo Finance Video

a month ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

SLS

Benzinga

a month ago

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Ford recalls more than 29,000 vehicles in the US, NHTSA says

SLS

Reuters

a month ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

SLS

GlobeNewswire

a month ago

SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

SLS

GlobeNewswire

2 months ago

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

SLS

GlobeNewswire

2 months ago

SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

SLS

GlobeNewswire

2 months ago

SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SLS

GlobeNewswire

2 months ago

SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SLS

MT Newswires

3 months ago

Sellas Life Sciences Says Group Data Show Tambiciclib Tops Benchmark for Median Overall Survival in Leukemia Study; Shares Up

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

SLS

GlobeNewswire

3 months ago

SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

SLS

GlobeNewswire

3 months ago

SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment

SLS

Clinical Trials Arena

4 months ago

Sellas reports Phase IIa trial data of SLS009 for DLBCL treatment

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SLS

GlobeNewswire

4 months ago

SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SLS

GlobeNewswire

5 months ago

SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SLS

MT Newswires

5 months ago

SELLAS Life Sciences Shares Fall; Interim Trial Results on Acute Myeloid Leukemia Treatment Issued

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SLS

GlobeNewswire

5 months ago

SELLAS Life Sciences Announces Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Key Business Objectives for 2025

SLS

GlobeNewswire

6 months ago

SELLAS Announces Key Business Objectives for 2025

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

SLS

GlobeNewswire

6 months ago

SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SLS

GlobeNewswire

7 months ago

SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

SLS

GlobeNewswire

7 months ago

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 in r/r AML

SELLAS announces data indicating key predictor of response to SLS009 in solid cancers

SLS

Clinical Trials Arena

7 months ago

SELLAS announces data indicating key predictor of response to SLS009 in solid cancers

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

SLS

GlobeNewswire

7 months ago

SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate

SLS

Simply Wall St.

8 months ago

We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SLS

GlobeNewswire

8 months ago

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

SLS

GlobeNewswire

8 months ago

SELLAS Life Sciences to Present at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition 2024

SLS

MT Newswires

9 months ago

SELLAS Life Sciences Gets FDA Rare Pediatric Disease Designation for Acute Myeloid Leukemia Immunotherapy

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SLS

GlobeNewswire

9 months ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

SLS

GlobeNewswire

9 months ago

SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory

SLS

Insider Monkey

9 months ago

Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

SLS

GlobeNewswire

a year ago

SELLAS Receives EMA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market

SLS

MT Newswires

a year ago

Sellas Life Sciences' Potential Leukemia Treatment Receives Second Rare Pediatric Disease Designation

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

SLS

GlobeNewswire

a year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

SLS

MT Newswires

a year ago

Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SLS

GlobeNewswire

a year ago

SELLAS Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SLS

GlobeNewswire

a year ago

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to SLS009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

SLS

GlobeNewswire

a year ago

SELLAS Announces Completion of Enrollment and Initial Positive Data in Phase 2a Trial of SLS009 in r/r AML

Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?

SLS

Simply Wall St.

a year ago

Can SELLAS Life Sciences Group (NASDAQ:SLS) Afford To Invest In Growth?

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Reports First Quarter 2024 Financial Results and Provides Corporate Update

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SLS

GlobeNewswire

a year ago

SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

SLS

GlobeNewswire

a year ago

SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

SLS

GlobeNewswire

a year ago

SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

SLS

GlobeNewswire

a year ago

SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget

SLS

Associated Press Finance

a year ago

First Capital: Q4 Earnings Snapshot

SLS

GlobeNewswire

a year ago

First Capital, Inc. Reports Annual And Quarterly Earnings

Phoenix Motor Inc. Announces Pricing of $4.8 Million Registered Direct Offering

SLS

ACCESSWIRE

a year ago

Phoenix Motor Inc. Announces Pricing of $4.8 Million Registered Direct Offering

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

SLS

GlobeNewswire

a year ago

CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference

Lantronix Appoints Christa Steele to Its Board of Directors

SLS

GlobeNewswire

a year ago

Lantronix Appoints Christa Steele to Its Board of Directors

Meta Materials Announces 1-for-100 Reverse Stock Split to Regain Nasdaq Compliance

SLS

ACCESSWIRE

a year ago

Meta Materials Announces 1-for-100 Reverse Stock Split to Regain Nasdaq Compliance

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

SLS

Zacks

a year ago

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

SLS

GlobeNewswire

a year ago

Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications

First Capital (NASDAQ:FCAP) shareholders have endured a 43% loss from investing in the stock three years ago

SLS

Simply Wall St.

a year ago

First Capital (NASDAQ:FCAP) shareholders have endured a 43% loss from investing in the stock three years ago

Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend

SLS

GlobeNewswire

a year ago

Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend

4 Stocks to Buy as Manufacturing Activity Makes Steady Progress

SLS

Zacks

a year ago

4 Stocks to Buy as Manufacturing Activity Makes Steady Progress

Sidoti Events, LLC's Virtual January Micro-Cap Conference

SLS

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Here's Why You Should Hold Zebra (ZBRA) in Your Portfolio

SLS

Zacks

a year ago

Here's Why You Should Hold Zebra (ZBRA) in Your Portfolio

16 Most Widely Held Stocks by Individuals

SLS

Insider Monkey

a year ago

16 Most Widely Held Stocks by Individuals

Intuitive Machines Enters into Warrant Exercise Transaction for $11.8 Million in Gross Proceeds

SLS

GlobeNewswire

a year ago

Intuitive Machines Enters into Warrant Exercise Transaction for $11.8 Million in Gross Proceeds

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

SLS

Zacks

a year ago

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

$SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients$

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

The 3 Best Penny Stocks to Buy in January 2024

SLS

InvestorPlace

a year ago

The 3 Best Penny Stocks to Buy in January 2024

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

SLS

Benzinga

a year ago

Cancer Cell Therapy Focused Marker Therapeutics Announces Pipeline Prioritization

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

SLS

Business Wire

a year ago

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

SLS

GlobeNewswire

a year ago

Aeries Technology to Participate at the 26th Annual ICR Conference

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

SLS

GlobeNewswire

a year ago

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

SELLAS Life Sciences Announces Proposed Public Offering

SLS

GlobeNewswire

a year ago

SELLAS Life Sciences Announces Proposed Public Offering

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

SLS

GlobeNewswire

a year ago

SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones

Analysts Expect Breakeven For Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Before Long

SLS

Simply Wall St.

2 years ago

Analysts Expect Breakeven For Hall of Fame Resort & Entertainment Company (NASDAQ:HOFV) Before Long

Web3 Winners: 3 Stocks to Invest in the Decentralized Web

SLS

InvestorPlace

2 years ago

Web3 Winners: 3 Stocks to Invest in the Decentralized Web

Canadian Investment Regulatory Organization Trading Halt - DGHI

SLS

CNW Group

2 years ago

Canadian Investment Regulatory Organization Trading Halt - DGHI

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

SLS

GlobeNewswire

2 years ago

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Modiv Industrial, Inc.'s (NYSE:MDV) Path To Profitability

SLS

Simply Wall St.

2 years ago

Modiv Industrial, Inc.'s (NYSE:MDV) Path To Profitability

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?

SLS

Simply Wall St.

2 years ago

How Did Aeries Technology, Inc's (NASDAQ:AERT) 13% ROE Fare Against The Industry?

SLS

GlobeNewswire

2 years ago

Kanen Wealth Management Issues Letter To Real Good Food Company, Inc.’s Board of Directors

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock

SLS

Zacks

2 years ago

Despite Fast-paced Momentum, Invitae (NVTA) Is Still a Bargain Stock

Linkage Global Inc Announces Closing of $6,000,000 Initial Public Offering

SLS

GlobeNewswire

2 years ago

Linkage Global Inc Announces Closing of $6,000,000 Initial Public Offering

LeddarTech Becomes a Publicly Traded Company After Completing Business Combination with Prospector Capital Corp., Will Commence Trading on Nasdaq Under Ticker Symbol "LDTC"

SLS

PR Newswire

2 years ago

LeddarTech Becomes a Publicly Traded Company After Completing Business Combination with Prospector Capital Corp., Will Commence Trading on Nasdaq Under Ticker Symbol "LDTC"

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

SLS

GlobeNewswire

2 years ago

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

Is Advantage Solutions (ADV) Trading an Attractive Upside-To-Downside Ratio?

SLS

Insider Monkey

2 years ago

Is Advantage Solutions (ADV) Trading an Attractive Upside-To-Downside Ratio?

Graphex Group Provides Important Updates on its Global Mine-to-Battery Solution, Including the Separation of its US Subsidiary Graphex Technologies LLC into a Standalone U.S. company, and Financing for a 200% Production Increase over Current Levels

SLS

Business Wire

2 years ago

Graphex Group Provides Important Updates on its Global Mine-to-Battery Solution, Including the Separation of its US Subsidiary Graphex Technologies LLC into a Standalone U.S. company, and Financing for a 200% Production Increase over Current Levels

Latest SELLAS Life Sciences Group Inc. (SLS) News on July 2, 2025

Share on Social Networks: